UAE-based Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has completed a deal with a Dutch company to launch a combination for the treatment of hypercholesterolemia, which is currently unavailable in the UAE market.
The license and technology transfer agreement with PharmaMatch was signed recently on the sidelines of CPhI Worldwide, the largest pharmaceutical trade fair in the world.
Under the terms of the agreement, Julphar will manufacture the combination, which is used to target hypercholesterolemia, a condition characterized by very high levels of cholesterol in the blood.
Jerome Carle, General Manager of Julphar, said: "Bringing new medicines to the local market is something we are very proud to be able to do. We strongly believe in the efficacy and value of these medications. They will have a real impact on the lives of the many people who suffer with high cholesterol.
“We are delighted to be partnering with PharmaMatch, a company with a strong reputation and track record in the European market and further afield.”
High blood cholesterol is a condition that causes the levels of certain bad fats, or lipids, to be too high in the blood. High blood cholesterol is one of the major risk factors for cardiovascular diseases (heart diseases), the leading cause of death in the UAE, which accounts for over two-thirds of all deaths in the country.
Subscribe to Arabian Business' newsletter to receive the latest breaking news and business stories in Dubai,the UAE and the GCC straight to your inbox.